Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9215130 | 0.93 | CYP1A2 (0.41) | CYP1A2ALDH1A1SRD5A1CYP3A4NOTUM | |
| SCHEMBL13344292 | 0.86 | ACHE (0.41) | ALDH1A1NOTUMACHEFFAR1 | |
| SCHEMBL25554148 | 0.83 | MTNR1A (0.44) | ALDH1A1SRD5A1CYP3A4ACHECA1 | |
| SCHEMBL345292 | 0.81 | DRD3 (0.57) | CYP4F2CYP4A11ACHECA1CA2 | |
| SCHEMBL345291 | 0.81 | DRD3 (0.57) | CYP4F2CYP4A11ACHECA1CA2 | |
| SCHEMBL24440190 | 0.80 | HDAC8 (0.42) | CYP1A2ALDH1A1CYP4F2CYP4A11NOTUM | |
| SCHEMBL29958290 | 0.80 | NOTUM (0.43) | SRD5A1CYP4F2CYP4A11NOTUMDRD2 | |
| SCHEMBL8370381 | 0.80 | ALDH1A1 (0.56) | ALDH1A1SRD5A1CYP4F2CYP4A11ADRB3 | |
| SCHEMBL31262473 | 0.80 | HDAC8 (0.42) | CYP1A2ALDH1A1CYP4F2CYP4A11NOTUM | |
| SCHEMBL27033717 | 0.80 | NOTUM (0.43) | SRD5A1CYP4F2CYP4A11NOTUMDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CYP1A2 4719/4885ALDH1A1 4654/4885SRD5A1 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.